Invesco S&P 500 Equal Weight Health Care ETF

RSPH

市值 US$9.29億

RSPH hits a new 52-week high, rising 29.5% from its low as resilient healthcare demand, solid earnings and defensive-sector appeal fuel momentum.

Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.

The Invesco S&P 500 Equal Weight Health Care ETF offers a lower expense ratio and broader diversification than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has generated higher 1-year and 5-year total returns while maintaining lower price volatility.

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Invesco S&P 500 Equal Weight Health Care ETF (RSPH), a passively managed exchange traded fund launched on November 1, 2006.

PBE offers a higher dividend yield and has delivered stronger one-year total returns. RSPH offers a more affordable expense ratio and a significantly lower historical drawdown.

The Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to 26 for the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF currently offers a significantly higher dividend yield and a lower expense ratio than its counterpart.

The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) was launched on 11/01/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Invesco Nasdaq Biotechnology ETF has a lower expense ratio but higher price volatility than Invesco S&P 500 Equal Weight Health Care ETF. Invesco S&P 500 Equal Weight Health Care ETF holds fewer stocks but uses an equal-weighting strategy to diversify across the large-cap healthcare sector.

The Invesco S&P 500 Equal Weight Health Care ETF provides broad exposure to the sector, while the State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry. The State Street SPDR S&P Pharmaceuticals ETF has significantly outperformed over the last year, though it carries higher concentration risk and historical volatility.

RSPH's valuation gap versus market weight peers has narrowed but not closed, with expected returns now roughly similar to XLV. RSPH's mid-cap tilt could in my opinion benefit more than XLV from falling financing costs if the Fed moves toward rate normalization. Annualized volatility for RSPH sits at 15.67%, close to XLV's 15.46%, limiting the diversification benefit of holding both.